Brian Woolford

Optometrist 👁

[Brian Woolford @WoolfordBrian]

@DonHollywood22

[Longevity Technology @LongevityTech]

Enzolytics partners with Khalpey #AI Lab on longevity #research initiative
Texas-based biotech Enzolytics has joined forces with Khalpey AI Lab in a partnership aimed at advancing the fields of #organregeneration and #longevity.
#digital
https://t.co/99dFVlTZZh

[Brian Woolford @WoolfordBrian]

@ImKingofPrussia IP portfolio on 🔥

[Brian Woolford @WoolfordBrian]

@Lower_Fox @KhalpeyLab Nice find!

[Brian Woolford @WoolfordBrian]

Just started my fourth round of IPF Immune. Never felt better! #SAGA #VIRO

[Brian Woolford @WoolfordBrian]

@JeffTaitano HIV patent ………

[Brian Woolford @WoolfordBrian]

Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA) https://t.co/7OeNLDayas

[Brian Woolford @WoolfordBrian]

@BiogenysisInc Congratulations!

[Brian Woolford @WoolfordBrian]

@GodfatherCap @ImKingofPrussia 💥 💥

[𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 @GodfatherCap]

$ENZC 🏆DEAL COMPLETE 🏆

𝙎𝘼𝙂𝘼𝙇𝙄𝘼𝙈 𝘼𝘾𝙌𝙐𝙄𝙎𝙄𝙏𝙄𝙊𝙉 𝘾𝙊𝙍𝙋. 𝘼𝙉𝙉𝙊𝙐𝙉𝘾𝙀𝙎 𝙀𝙓𝙀𝘾𝙐𝙏𝙄𝙊𝙉 𝙊𝙁 𝘿𝙀𝙁𝙄𝙉𝙄𝙏𝙄𝙑𝙀 𝘽𝙐𝙎𝙄𝙉𝙀𝙎𝙎 𝘾𝙊𝙈𝘽𝙄𝙉𝘼𝙏𝙄𝙊𝙉 𝘼𝙂𝙍𝙀𝙀𝙈𝙀𝙉𝙏💥💥💥

The Company has executed a binding business combination agreement for the purchase of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), operating subsidiaries of Enzolytics Inc. (OTC PK: ENZC). The combined company is expected to trade on NASDAQ.

Congrats everyone!
Major milestones just achieved. 🏆

$SAGA Executive Team, @enzolytics Team, @drgauravchandra, and all patient shareholder! 💥💥💥💥

Winning! 🏆

https://t.co/3q01PCFO6x

[Biogenysis @BiogenysisInc]

#BGEN is strategically pursuing collaborations, licensing, & partnerships for 19 viruses. According to Polaris Market Research, the global market size for #MonoclonalAntibodies is projected to reach $ 479.13 billion by 2030. strategic IP portfolio #AI
https://t.co/zIKRCXUhVU

[Gaurav Chandra M.D. @drgauravchandra]

#BGEN has a well-defined IP portfolio aligned with a licensing strategy. Our #monoclonalantibodies, both IgG and IgA, being universal, broadly neutralizing, durable, and unaffected by mutations, are critical solutions for COVID-19 mutations. The Company aims to collaborate, license, or partner with pharma entities for 19 viruses in our repetoire for diagnostics, therapeutics, and vaccines. #SAGA #SPAC will make this possible. @BiogenysisInc https://t.co/0bkSjiujTt
#SARSCOV2 #nasal #patent #AI #PCT #sciencealwayswins

[Brian Woolford @WoolfordBrian]

@GodfatherCap

[Brian Woolford @WoolfordBrian]

@alsvigor @Demi6851 7 weeks is tomorrow. 💥

[Brian Woolford @WoolfordBrian]

@GodfatherCap We should also see Covid patent reach publication phase. 🔥

[Brian Woolford @WoolfordBrian]

@GodfatherCap

[Brian Woolford @WoolfordBrian]

@DonHollywood22 Exactly!

[Brian Woolford @WoolfordBrian]

@DonHollywood22 Per @Demi6851 post the COVID patent could reach publication phase within 2 weeks. 💥

[Brian Woolford @WoolfordBrian]

@DonHollywood22 The cherry on top for me will be the valuation of the AI platform. It’s going to be huge!

[Gaurav Chandra M.D. @drgauravchandra]

Our dedication to revolutionizing drug discovery through the power of AI is exemplified through our recent partnership.Our AI platform is at the forefront of transforming healthcare by shifting it from a reactive approach to one that is predictive, preventive, personalized, and participatory. Our ultimate aim is to identify early biomarkers for Alzheimer's disease and discover new therapeutic targets that can impede its progression. Our AI model incorporates genetics, nutrition, and #microbiome, and can be effectively utilized for other chronic illnesses as well. #Alzheimers #ENZC #AI @BiogenysisInc #P4Medicine https://t.co/HaatRwqOR5